Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 2
2013 5
2014 5
2015 8
2016 2
2017 6
2018 6
2019 5
2020 9
2021 12
2022 9
2023 10
2024 8
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85 results

Results by year

Filters applied: . Clear all
Page 1
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, Haas GP, Kim CS, Ramirez-Backhaus M, Rannikko A, Tarazi J, Sridharan S, Sugg J, Tang Y, Tutrone RF Jr, Venugopal B, Villers A, Woo HH, Zohren F, Shore ND; EMBARK Study. Freedland SJ, et al. N Engl J Med. 2023 Oct 19;389(16):1453-1465. doi: 10.1056/NEJMoa2303974. N Engl J Med. 2023. PMID: 37851874 Clinical Trial.
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.
Au L, Hatipoglu E, Robert de Massy M, Litchfield K, Beattie G, Rowan A, Schnidrig D, Thompson R, Byrne F, Horswell S, Fotiadis N, Hazell S, Nicol D, Shepherd STC, Fendler A, Mason R, Del Rosario L, Edmonds K, Lingard K, Sarker S, Mangwende M, Carlyle E, Attig J, Joshi K, Uddin I, Becker PD, Sunderland MW, Akarca A, Puccio I, Yang WW, Lund T, Dhillon K, Vasquez MD, Ghorani E, Xu H, Spencer C, López JI, Green A, Mahadeva U, Borg E, Mitchison M, Moore DA, Proctor I, Falzon M, Pickering L, Furness AJS, Reading JL, Salgado R, Marafioti T, Jamal-Hanjani M; PEACE Consortium; Kassiotis G, Chain B, Larkin J, Swanton C, Quezada SA, Turajlic S; TRACERx Renal Consortium. Au L, et al. Cancer Cell. 2021 Nov 8;39(11):1497-1518.e11. doi: 10.1016/j.ccell.2021.10.001. Epub 2021 Oct 28. Cancer Cell. 2021. PMID: 34715028 Free PMC article.
Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nolè F, Staffurth J, Redfern C, Sáez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH; TRITON3 Investigators. Fizazi K, et al. Among authors: pintus e. N Engl J Med. 2023 Feb 23;388(8):719-732. doi: 10.1056/NEJMoa2214676. Epub 2023 Feb 16. N Engl J Med. 2023. PMID: 36795891 Free PMC article. Clinical Trial.
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study.
Abida W, Campbell D, Patnaik A, Bryce AH, Shapiro J, Bambury RM, Zhang J, Burke JM, Castellano D, Font A, Ganju V, Hardy-Bessard AC, McDermott R, Sautois B, Spaeth D, Voog E, Piulats JM, Pintus E, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Loehr A, Despain D, Simmons AD, Dowson M, Go J, Watkins SP, Chowdhury S. Abida W, et al. Among authors: pintus e. Eur Urol. 2023 Sep;84(3):321-330. doi: 10.1016/j.eururo.2023.05.021. Epub 2023 Jun 3. Eur Urol. 2023. PMID: 37277275 Free PMC article. Clinical Trial.
Copy number architectures define treatment-mediated selection of lethal prostate cancer clones.
Hasan AMM, Cremaschi P, Wetterskog D, Jayaram A, Wong SQ, Williams S, Pasam A, Trigos A, Trujillo B, Grist E, Friedrich S, Vainauskas O, Parry M, Ismail M, Devlies W, Wingate A, Linch M, Naceur-Lombardelli C; PEACE consortium; Swanton C, Jamal-Hanjani M, Lise S, Sandhu S, Attard G. Hasan AMM, et al. Nat Commun. 2023 Aug 10;14(1):4823. doi: 10.1038/s41467-023-40315-9. Nat Commun. 2023. PMID: 37563129 Free PMC article.
Stem Cells in Osteochondral Tissue Engineering.
Pintus E, Baldassarri M, Perazzo L, Natali S, Ghinelli D, Buda R. Pintus E, et al. Adv Exp Med Biol. 2018;1058:359-372. doi: 10.1007/978-3-319-76711-6_16. Adv Exp Med Biol. 2018. PMID: 29691830 Review.
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial.
Leone G, Orlando F, Dutey-Magni P, Vainauskas O, Grist E, Ciani Y, Lall S, Thakali S, Wingate A, Wetterskog D, Sachdeva A, Sydes MR, McPhail N, Sreenivasan T, O'Sullivan JM, Clarke NW, Parmar MKB, Brown LC, James ND, Demichelis F, Attard G; STAMPEDE collaborators. Leone G, et al. JAMA Oncol. 2025 Feb 27;11(4):426-9. doi: 10.1001/jamaoncol.2024.7051. Online ahead of print. JAMA Oncol. 2025. PMID: 40014335
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.
Gillessen S, Murphy L, James ND, Sachdeva A, El-Taji O, Abdel-Aty H, Adler AI, Amos C, Attard G, Varughese M, Gale J, Brown S, Srihari N, Birtle AJ, Brown M, Chan K, Chowdhury S, Cross W, Dearnaley DP, Din O, Dutey-Magni P, Gilbert DC, Gilson C, Gray S, Grist E, Hofmann U, Hudson AM, Jain Y, Jeyasangar G, Jones R, Kayani M, Langley RE, Malik Z, Mason MD, Matheson D, McAlpine C, Macnair A, Millman R, Murphy C, Padden-Modi M, Parikh O, Parker C, Rush H, Russell M, Srinivasan R, Sundar S, Tanguay JS, Turco F, Williams P, Sydes MR, Parmar MKB, Brown LC, Clarke NW; STAMPEDE investigators. Gillessen S, et al. Lancet Oncol. 2025 Aug;26(8):1018-1030. doi: 10.1016/S1470-2045(25)00231-1. Epub 2025 Jul 7. Lancet Oncol. 2025. PMID: 40639383 Free PMC article. Clinical Trial.
85 results